Search the Newsreel

Annexon shares fall 6% on wider-than-expected quarterly loss

Annexon (NASDAQ:ANNX) reported a second-quarter loss of $0.28 per share, which was wider than the analyst consensus of $0.24 per share, leading to a 6.37% fall in pre-market trading. The biopharmaceutical company attributed the increased loss to higher spending on its late-stage clinical programs, …

Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study

Annexon, Inc. has announced an expansion to its Phase 3 ARCHER II trial for vonaprument, a treatment for dry age-related macular degeneration with geographic atrophy. The expansion includes adding a Month 24 dual primary endpoint to complement the existing Month 15 primary endpoint, alongside …

Annexon (NASDAQ: ANNX) reports $99.5M H1 2026 loss and secures new $200M debt facility

Annexon Releases Q2 2026 Financial Results

Annexon, Inc. (ANNX) reported a Q2 2026 basic and diluted loss per share of $0.28, an improvement from $0.34 in the prior year. The clinical-stage biopharmaceutical company posted a net loss of $55.3 million as it continues to invest in its pipeline for inflammatory-related …

Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Estimates By $0.05 EPS

Annexon (NASDAQ:ANNX) reported second-quarter earnings, missing analysts' consensus estimates by $0.05 with a loss of $0.28 per share. Despite the earnings miss, the company highlighted positive clinical trial data for tanruprubart in Guillain-Barré syndrome and expanded its ARCHER II geographic atrophy trial. Annexon also …

Annexon (NASDAQ:ANNX) Shares Gap Down on Disappointing Earnings

Annexon Q2 Earnings Call Highlights

Annexon (ANNX) announced an expansion of its ARCHER II trial for vonaprument in geographic atrophy, adding a 24-month primary endpoint to capture longer-term efficacy data, alongside the existing 15-month endpoint. The company also provided updates on its Guillain-Barré syndrome (GBS) program, with tanruprubart advancing …

Earnings call transcript: Annexon misses Q2 2026 EPS view as shares fall premarket

Annexon reported a wider-than-expected Q2 2026 loss of $0.28 per share, leading to a 6.37% premarket stock decline. Despite the earnings miss, the clinical-stage biotech highlighted positive clinical progress for its Guillain-Barré syndrome program, tanruprubart, and expanded the ARCHER II geographic atrophy trial to …

Earnings Flash (ANNX) Annexon Posts Q2 Loss $0.28 a Share, vs. FactSet Est of $0.23 Loss

Annexon (Nasdaq: ANNX) deepens pipeline, adds $200M credit facility and new endpoints

Annexon (Nasdaq: ANNX) reported its second-quarter 2026 financial results, including a net loss of $55.3 million, but also announced a new $200 million credit facility to extend its cash runway into 2028. The company is advancing its neuroinflammatory pipeline, expanding the Phase 3 ARCHER …

Tanruprubart Shows Rapid Responses in First FORWARD Cohort for Guillain-Barre Syndrome

Annexon reported rapid, clinically meaningful improvements in strength among all 10 patients in the first US and European cohort of its open-label FORWARD study for Guillain-Barré syndrome (GBS) following a single tanruprubart infusion. These results, including ambulation for bedbound patients and ventilator liberation, are …

Form 8K Annexon Inc For: 10 August By Investing.com

This article announces that Annexon Inc. filed a Form 8K on August 10th. The filing is brief and does not contain additional details beyond the date of the filing and the company involved.

Annexon appoints retinal surgeon Blumenkranz to board By Investing.com

Annexon, Inc. (NASDAQ:ANNX) has appointed retinal surgeon Mark S. Blumenkranz, M.D., M.M.S., to its board of directors. Concurrently, Muneer Satter will step down from the board after more than 11 years of service. Blumenkranz brings extensive experience from Stanford University and has co-founded several …

Annexon names Mark Blumenkranz to board as Muneer Satter steps down

Annexon has appointed retinal surgeon and biotech entrepreneur Mark S. Blumenkranz to its board of directors. Blumenkranz, a Stanford ophthalmology professor emeritus and co-director of its Ophthalmic Innovation Program, has a strong background in founding and leading ophthalmic companies. This appointment follows the stepping …

Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors

Annexon, Inc. (Nasdaq: ANNX) has appointed Dr. Mark S. Blumenkranz, a distinguished retinal surgeon and biotechnology entrepreneur, to its board of directors. Dr. Blumenkranz brings over four decades of experience in retinal disease innovation, which will be crucial as Annexon advances its late-stage clinical …

Renaissance Technologies LLC Sells 258,300 Shares of Annexon, Inc. $ANNX

Renaissance Technologies LLC reduced its stake in Annexon, Inc. (NASDAQ:ANNX) by 32.2%, selling 258,300 shares but still retaining 544,300 shares valued at approximately $3.0 million. While Renaissance Technologies reduced its holdings, other institutional investors like AQR Capital Management and Acadian Asset Management increased their …

Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week

Annexon, Inc. announced early positive results from the first ten U.S. and European patients in its open-label FORWARD study for Guillain-Barré syndrome (GBS) treated with tanruprubart. The study demonstrated rapid, clinically meaningful improvements in strength and reduced disability within days of a single infusion, …

Annexon Inc (ANNX) Stock News Today

This article provides an update on Annexon Inc (ANNX) stock news, earnings, analyst ratings, and key developments. It notes that more news is expected soon and invites users to stay tuned. The article also presents current stock performance data for ANNX.

Wells Fargo Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $27

Wells Fargo has reaffirmed its Buy rating on Annexon (ANNX.US), holding its target price at $27. This continued endorsement suggests the firm's confidence in Annexon's future performance.

State Street Corporation (ANNX) discloses 9.8M-share, 6% holding in Annexon

State Street Corporation has disclosed a 6% holding in Annexon Inc. (ANNX), amounting to 9,824,321 common shares, as per a Schedule 13G filing. The shares are held for passive investment purposes with shared voting power over 9,572,419 shares and shared dispositive power over all …

Goldman Sachs reiterates Neutral on Annexon stock after GBS data

Goldman Sachs has reiterated a Neutral rating and $7.00 price target on Annexon Biosciences (NASDAQ: ANNX) following the release of initial data from its FORWARD study for Guillain-Barré syndrome (GBS). The study showed rapid and meaningful improvement in patients, supporting a planned biologics license …

Annexon says tanruprubart shows rapid strength gains in first 10 GBS FORWARD study patients

Annexon reported positive early results from its FORWARD study for Guillain-Barré syndrome, demonstrating rapid functional and strength gains in all ten treated patients within approximately one week. The company noted that patients, including severe cases, showed quicker recovery than expected, and the safety profile …

Annexon Announces Positive Clinical Outcomes from GBS FORWARD Study on Tanruprubart

Annexon, Inc. reported positive clinical outcomes from the initial U.S. and European patient cohort of its GBS FORWARD Study. The study is evaluating tanruprubart, and the findings were disclosed in a current report filed with the SEC on August 6, 2026. This announcement highlights …

Form 8K Annexon Inc For: 6 August By Investing.com

This article from Investing.com reports on an 8K filing by Annexon Inc. for August 6th, 2026. The content provides basic details of the filing along with an image credited to Reuters. The article itself is very brief and mostly surrounded by financial market data, …

Annexon (ANNX) Projected to Post Earnings on Thursday

Annexon (NASDAQ:ANNX) is projected to release its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.23 per share and revenue of $6.50 million. The company's stock recently traded near $5.37, and analyst sentiment is mixed, resulting …

Annexon secures USD 200m credit facility to fund late-stage programs through potential commercial launch

Annexon, Inc. has secured a senior secured credit facility of up to $200 million from Oxford Finance LLC. This non-dilutive capital is intended to fund the company's late-stage programs, tanruprubart and vonaprument, through potential commercial launch, avoiding additional equity dilution. The funding is tied …

Annexon, Inc. (NASDAQ:ANNX) Receives Average Recommendation of "Hold" from Analysts

Annexon, Inc. (NASDAQ:ANNX) has received an average "Hold" recommendation from ten analysts, with a 12-month average price target of $15.33 against its recent trading price of $5.07. Insider transactions show significant share purchases by directors William H. Carson and Muneer A. Satter, increasing insider …

BlackRock, Inc. Expands Stake in Annexon Inc (ANNX) with Strategic Share Acquisition

BlackRock, Inc. has significantly increased its stake in Annexon Inc (ANNX) by acquiring over 2.1 million shares, bringing its total holdings to 13.1 million shares, representing an 8% position. This strategic move highlights BlackRock's calculated bet on the long-term potential of the clinical-stage biopharmaceutical …

Annexon secures $200M credit facility with Oxford Finance

Annexon, Inc. (NASDAQ:ANNX) has secured a credit facility worth up to $200 million with Oxford Finance LLC to fund its drug development programs for neuroinflammatory diseases. The biopharmaceutical company received an initial $50 million, with additional funds tied to the achievement of milestones for …

Annexon (Nasdaq: ANNX) obtains up to $200M credit facility from Oxford

Annexon, Inc. secured a credit facility of up to $200 million from Oxford Finance LLC to support its working capital and general business requirements, including advancing its vonaprument and tanruprubart registrational programs. An initial $50 million was funded at closing, with additional tranches tied …

Annexon Secures Up to $200 Million Term Loan Facility With Oxford Finance

Annexon (ANNX) has secured a term loan facility of up to $200 million from Oxford Finance for working capital and general corporate purposes. An initial $50 million was funded at signing, with additional tranches totaling up to $150 million tied to milestones and mutual …

Annexon Inc (ANNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Annexon Inc (ANNX), detailing its performance based on various indicators and moving averages. It presents a summary of technical indicators like MACD, RSI, and CCI, as well as moving average values from MA5 to MA200, highlighting neutral …

Several Annexon Insiders Sell Shares Sending Potential Negative Signal

The article reports that several Annexon insiders have sold shares, potentially signaling a negative outlook for the company. This move often raises concerns among investors regarding the company's future performance.